MTZ

DRUG2 trials

Sponsors

Pfizer, Institute of Hematology & Blood Diseases Hospital, China

Conditions

AML, AdultComplicated Intra-abdominal InfectionHosptial Acquired PneumoniaVentilator Associated Pneumonia

Phase 3

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

CompletedNCT03329092

PfizerComplicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia

Start: 2018-04-05End: 2023-02-23Updated: 2024-12-10

Unknown Phase

MRD-positive AML Clinical Study

RecruitingNCT07131059

Institute of Hematology & Blood Diseases Hospital, ChinaAML, Adult

Start: 2024-05-11End: 2028-04-30Target: 120Updated: 2025-08-20

Related Papers

Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam-Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales.

2025-11-21

Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients

Antimicrobial Agents and Chemotherapy2025-06-188 citations

P-1256. Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Aztreonam-Avibactam Dosing Regimens

Open Forum Infectious Diseases2025-01-292 citations

Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.

2024-10-0751 citations

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation

European Journal of Clinical Pharmacology2024-01-2222 citations

2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study

Open Forum Infectious Diseases2023-11-2725 citations

Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain

BMJ Open2022-02-012 citations